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ABSTRACT 
Osteoblast differentiation of bone-marrow derived human mesenchymal stem cells (hMSC) can 
be induced by stimulation with either canonical Notch ligand, Jagged1, or bone morphogenetic 
proteins (BMP). However, it remains elusive how these two pathways lead to the same phenotypic 
outcome. Since Runx2 is regarded as a master regulator of osteoblastic differentiation, we targeted 
Runx2 with siRNA in hMSC. This abrogated both Jagged1 and BMP2 mediated osteoblastic 
differentiation, confirming the fundamental role for Runx2. However, while BMP stimulation 
increased Runx2 and downstream Osterix protein expression, Jagged1 treatment failed to 
upregulate either, suggesting that canonical Notch signals require basal Runx2 expression. To fully 
understand the transcriptomic profile of differentiating osteoblasts, RNA sequencing was 
performed in cells stimulated with BMP2 or Jagged1. There was common upregulation of ALPL 
and extracellular matrix genes, such as ACAN, HAS3, MCAM, and OLFML2B. Intriguingly, genes 
encoding components of Notch signaling (JAG1, HEY2 and HES4) were among the top 10 genes 
upregulated by both stimuli. Indeed, ALPL expression occurred concurrently with Notch activation 
and inhibiting Notch activity for up to 24 hours after BMP administration with DAPT (a gamma 
secretase inhibitor) completely abrogated hMSC osteoblastogenesis. Concordantly, RBPJ 
(Recombination Signal Binding Protein for Immunoglobulin Kappa J Region, a critical 
downstream modulator of Notch signals) binding could be demonstrated within the ALPL and SP7 
promoters. As such, siRNA mediated ablation of RBPJ decreased BMP-mediated 
osteoblastogenesis. Finally, systemic Notch inhibition using diabenzazepine (DBZ) reduced 
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BMP2-induced calvarial bone healing in mice supporting the critical regulatory role of Notch 
signaling in BMP-induced osteoblastogenesis. 




While BMPs are potent osteoblastogenic agents, the role for Notch signaling in osteoblastogenesis 
has been controversial. In addition to activating canonical SMAD protein, BMPs also lead to 
increased Notch receptor processing, Notch target gene expression, and Notch ligand Jagged1 
upregulation. Blocking canonical Notch signaling ablates BMP-induced osteoblastogenesis but not 
BMP signaling. Given that Jagged1 stimulation alone drives osteoblastic differentiation of hMSCs, 
and that loss-of-function mutations in the Jagged1 gene causes low bone mass and osteopenia in 
humans, decreases in Jagged1 ligand during osteoblastogenesis may contribute to reduced bone 
formation by affecting activity of classical osteoanabolic factors, such as BMP.  
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INTRODUCTION 
Signaling molecules that play a major role in patterning of the developing embryo are capable of 
significantly affecting osteoblast differentiation of primary bone marrow-derived mesenchymal 
progenitor cells (MSCs) [1].  These include members of the bone morphogenetic protein (BMP) 
family, the transforming growth factor β (TGF-β) superfamily, fibroblast growth factors (FGFs), 
the Wnt family of secreted factors, and hedgehog and Notch pathway ligands [2 3]. It is now well 
established that integration of multiple signals with sequential activation of transcription factors 
during various stages of differentiation is key to properly drive osteoblastogenesis [2]. 
Since their initial discovery over 60 years ago, over 20 BMP family members have been identified 
and characterized [4]. Studies in transgenic and knockout mice and in humans with naturally 
occurring mutations have established that BMP signaling also impacts heart, neural and cartilage 
development apart from their role in postnatal bone formation [4 5]. Among the BMP family 
members, BMP2, BMP4, BMP6, BMP7 and BMP9 are all known to promote osteoblastic 
differentiation of MSCs both in vitro and in vivo [6]. Upon ligand binding, BMPs recruit a hetero-
tetrameric receptor complex and initiate a canonical signal transduction cascade consisting of 
SMAD and TAK1 dependent signaling (leading to the activation of mitogen-activated protein 
kinase (MAPK)) that converge on classical osteoblastic transcription factors Runx2, Dlx5 and 
Osterix to orchestrate osteoblast differentiation of MSCs [3 7]. In addition, BMP signals crosstalk 
with Wnt, Hedgehog, PTHrP, FGF and Notch signaling to co-ordinate bone homeostasis in vivo 
[7].  
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Notch signaling is a key cell-to-cell communication pathway that controls multiple stem-cell fates 
such as proliferation, self-renewal, and differentiation during embryonic development and 
postnatal life [8]. Ligand-mediated Notch activation involves a series of proteolytic cleavages of 
the Notch family of receptors (Notch 1-4) in signal receiving cells, which releases the intracellular 
Notch domain into the cytoplasm (NICD) [9]. The released NICD translocates from the cytoplasm 
to the nucleus and initiates transcription of the Notch target genes by interacting with DNA binding 
CSL/RBP-J protein, MAML (the transcriptional coactivator, mastermind-like-1), and other 
transcription factors [10]. Previous studies examining the role of Notch signaling in osteoblast 
differentiation often have produced conflicting reports. However, abolishing Notch ligand Jagged-
1 signaling in mouse models has successfully recapitulated some of the skeletal abnormalities seen 
in Alagille patients, who harbor inactivating mutations of Jagged1 [11 12]. In agreement with 
Notch signaling being osteoanabolic, reports from our laboratory have shown that culturing hMSC 
in presence of Jagged1 induces osteoblast differentiation via a PKC delta dependent mechanism 
[10 13] and that intraoperative delivery of the Notch ligand Jagged1 using collagen scaffolds 
regenerates appendicular and craniofacial bone defects in rodents [14]. 
 In recent years, increasing number of studies have reported that BMP and Notch signals crosstalk 
with each other to either enhance [15 16] or antagonize each other [17] during osteogenesis. Hill 
et al. observed that Jagged1 knockout in mouse cranial neural crest cells caused maxillary 
hypoplasia, and inhibiting Jagged1 expression significantly decreased the mineralization potential 
of mouse embryonic maxillary mesenchymal cells in response to BMP stimulation [18]. Moreover, 
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Hey1, a canonical Notch target gene can be induced by BMP stimulation of hMSCs, MC3T3, 
C2C12 and in mouse calvarial cells [19]. Since most of BMP-Notch crosstalk studies are based on 
rodent models, there is a paucity of data in the human setting. Although clear skeletal 
malformations are observed in patients with Alagille syndrome, who harbor inactivating Notch 
mutations, it is not clear if canonical Notch signals co-operate with canonical BMP signals and/or 
classical osteogenic transcription factors Runx2 and Osterix. Herein we explored the 
transcriptomic profile of differentiating human osteoblasts and discovered that canonical Notch 
signal itself is a major driver of human osteoblastogenesis and has a major regulatory role during 
BMP stimulation of hMSCs. Our results demonstrate that BMP signaling results in concomitant 
activation of Notch signaling and alkaline phosphatase expression, and that blocking Notch 
signaling abrogates early-phases of human osteoblast differentiation.  
 
Materials and Methods 
Culture and treatment of human mesenchymal stem cells: 
Primary bone-marrow derived human mesenchymal stem cells (hMSC) derived from healthy 
donors (age range 22 years to 29 years) pre-characterized for cell surface expression (CD166+ 
CD90+ CD105+ CD36- CD34- CD10- CD11b- CD45-) and tri-lineage differentiation 
(osteoblastic, adipogenic and chondrogenic) potential at the Institute of Regenerative Medicine, 
Texas A&M University were used throughout the study. For routine maintenance of hMSCs, cells 
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were cultured at a density of 3000 cells/cm2 using alpha-MEM supplemented with 16.5% FBS 
(Atlas Biologicals, CO) in standard culture conditions. Jagged1 (R&D Systems, MN) stimulation 
was carried out by  immobilizing recombinant human Jagged1 onto tissue culture plates with minor 
modifications as previously described [10 13],  whereas bone morphogenetic protein (BMP) 
stimulation was carried out by adding 300 ng/ml of recombinant human/mouse/rat BMP-2 or 
BMP-6 (R&D Systems, MN) to the cultured cells. Briefly, recombinant human Jagged1 (5 µg/ml 
in sterile phosphate buffered saline) solution was coated onto tissue culture plates for 1 h at 37ºC. 
hMSC harvested from routine maintenance media were re-suspended at a density of 60,000cells/ml 
using serum-containing osteogenic media (routine maintenance media additionally supplemented 
with 25 µg/ml Ascorbic acid-2-phosphate (AA2P), 5 mM beta-glycerophosphate (BGP) and 1% 
insulin-transferrin-selenous acid (ITS)) and directly plated onto the Jagged1 coated dish. After 3 
days of Jagged1 stimulation, cells were harvested for RNA, protein, histochemical alkaline 
phosphatase detection or received fresh osteogenic media (every 2 days after the first 3 days) until 
stained for alizarin red S (typically within 10 days after plating the cells onto the Jagged1 coated 
dish). For BMP treatment, 15,000 cells/cm2 were plated using serum-containing osteogenic media 
for 2 days and stimulated with recombinant BMPs (300 ng/ml) in serum-free osteogenic media. 
BMP stimulated cells were harvested after 3 days for RNA and protein, and after 3-4 days for 
histochemical alkaline phosphatase detection or received fresh serum-free osteogenic media (every 
2 days after the first 3 days) until stained for Alizarin red S (typically within 10 days after BMP 
stimulation).  
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Small interfering RNA transfection of hMSCs: 
Small interfering RNA for Runx2 was purchased from Ambion (Cat. No: AM16708) and set of 4 
ON-TARGETplus Human RBPJ siRNA (LQ-007772-00-0002) was obtained from Dharmacon 
Inc. One day before siRNA transfection, 60,000 hMSCs were seeded onto each well of a 12-well 
plate using hMSC maintenance media and the next day transfected using DharmaFECT1 
transfection reagent (Dharmacon Inc., Lafayette, CO) following manufacturer’s instructions. 
siRNA transfected cells were allowed to recover for 2 days and either directly stimulated with 300 
ng/ml of BMP (using serum-free osteogenic media) or collected by trypsinization and replated 
onto Jagged1 coated dishes using osteogenic media containing serum. Total RNA and protein were 
harvested from the transfected cells after 3 days of stimulation with Jagged1 or BMP2. 
Histochemical alkaline phosphatase expression was also determined at 3 days post stimulation. 
For Alizarin red S staining, cells received fresh osteogenic media every other day after 3 days of 
stimulation for 8-10 days. 
Alkaline Phosphatase and Alizarin Red Staining: 
At the end of treatment period (after 3-4 days depending on the experiment), multi-well plates 
were processed for alkaline phosphatase staining using Leukocyte Alkaline Phosphatase Kit 
(SIGMA) following manufacturer’s instructions. For Alizarin Red S staining (usually at day 10 
after treatment), each well was gently washed with PBS and fixed for 1 h using 4% neutral buffered 
paraformaldehyde solution. The fixative solution was removed from each well, rinsed once with 
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deionized water and an Alizarin Red S solution (1%, pH = 4.2) was added for 20 minutes. Excess 
stain solution was aspirated from each well and rinsed twice with deionized water. Stained plates 
were allowed to air-dry for 24 hours before processing for digital image analysis.  
Relative Alkaline phosphatase stain and Alizarin red S stain was digitally quantified as described 
previously [20] . Each stained well was scanned using high-resolution color brightfield objective 
(1.25X) of the Lionheart FX automated microscope (BiotTek). For each scanned well, Image J 
software was used to digitally enumerate integrated density values within cell monolayers 
according to the guidelines provided by the National Institute of Health. Data was combined from 
at least 3 different donor lines and represented as average fold-change. 
Quantitative RT-PCR analysis: 
Total RNA was isolated from stimulated cells using TRIzol reagent (Invitrogen, CA) and 
quantified using a NanoDrop 2000 spectrophotometer (Thermo Scientific). 600 ng of total RNA 
was reverse transcribed using High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems) in a 20 µl reaction. The resulting cDNA was diluted three times and one microliter 
was amplified using Power SYBR® Green PCR Master Mix and gene-specific primers in a 7500 
Fast Real-Time PCR System (Applied Biosystems) following manufacturer’s recommendations. 
The sequences of primers used are provided in the supplementary information. Relative expression 
for each gene was normalized against GAPDH and expressed as fold change over control. Data 
from at least 3 different donor lines were combined and reported as mean±standard deviation.  
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Immunoblotting: 
Immunoblotting was performed using standard procedures as described previously [20][21]. 
Briefly, hMSC monolayers were washed three times with ice-cold PBS, and lysis buffer composed 
of 50 mM Tris-Cl, 150 mM NaCl, 0.1% SDS, 0.1% Igepal CA 630, 0.5% sodium deoxycholate, 
and protease inhibitor cocktail (Roche) was added. Cell lysates were collected, vortexed 
vigorously, and clarified by centrifugation. The protein concentrations in the supernatant were 
determined using BCA protein assay (Pierce). 10-20 micrograms of each lysate were loaded into 
SDS-polyacrylamide gels and electro transferred onto polyvinyl difluoride membranes. 
Membranes were blocked for 1 h in 2.5 % non-fat skim milk in T-TBS (Tris-buffered saline 
containing 0.01% Tween-20), then incubated overnight at 4 ˚C with primary antibodies (see below 
for antibody information). Membranes were washed three times with T-TBS, then incubated with 
horse-radish-peroxidase conjugated secondary antibodies for 1 h at room temperature. Finally, the 
blots were incubated for 5 min in Supersignal™ West Femto Chemiluminescent Substrate (Fisher 
Scientific) and data were captured on Bio-Rad Chemi Doc system using appropriate settings for 
each antibody. Relative band intensities from each blot were calculated using Image Lab software 
v5.2.1 (Bio-Rad) and data from 3-4 different donor lines were combined for statistical analysis. 
The following primary and secondary antibodies were used: RUNX2 (D1L7F) Rabbit mAb (Cell 
Signaling Technology, 12556S, 1:1000); Anti-SP7/Osterix antibody-ChIP Grade (Abcam, 
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ab22552, 1:3000), RBPSUH (D10A4) XP® Rabbit mAb (Cell Signaling Technology, 5313S, 
1:1000), Phospho-SMAD1 (Ser463/465)/Smad5 (Ser463/465)/Smad9 (Ser465/467) (D5B10) 
Rabbit mAb (Cell Signaling Technology, 13820S, 1:1000), Cleaved Notch1 (Val1744) (D3B8) 
Rabbit mAb (Cell Signaling Technology, 4147S, 1:1000), Notch2 (D76A6) XP® Rabbit mAb 
(Cell Signaling Technology, 5732S, 1:2000), Notch3 (D11B8) Rabbit mAb (Cell Signaling 
Technology, 5276S, 1:3000), GAPDH (Cell Signaling Technology, 5174S, 1:30000), Anti-rabbit 
IgG, HRP-linked antibody (Cell Signaling Technology, 7074S, 1:5000), and Anti-mouse IgG, 
HRP-linked antibody (Cell Signaling Technology, 7076S, 1:5000). 
RNA sequencing: 
Total RNA was isolated from cells stimulated with Jagged1 or BMP for 3 days using TRIzol 
reagent following manufacturer’s instructions. RNA clean-up and on-column DNase digestion was 
performed using RNeasy® Mini-Kit (Qiagen) following standard procedures. Total RNA samples 
were processed for library preparation and sequencing as previously described [20]. Briefly, rRNA 
was depleted from the total RNA samples using Ribo-Zero rRNA Removal Kit (Illumina). RNA-
seq libraries were prepared using the NEBNext Ultra II Directional RNA library Prep Kit for 
Illumina (NEB) following standard protocols. Libraries were sequenced on one S2 flow cell on an 
Illumina NovaSeq 6000, generating ~200 million paired-end 50 bp reads per sample. RNA-seq 
data were aligned to the hg19 genome with STAR v.2.5b [22] and pre-processed with PORT 
(https://github.com/itmat/Normalization) using the GENCODE Release 19 (GRCh37.p13) 
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annotation plus annotation for lincRNAs and sno/miRNAs from the UCSC Table Browser 
(downloaded 7/7/2016). Normalized PORT counts for the uniquely mapped read pairs to the sense 
strand were additionally normalized by gene size and the resulting values were used in the 
computation of gene expression percentiles.  
Chromatin Immunoprecipitation: 
Chromatin Immunoprecipitation (ChIP) assays were performed as reported previously with minor 
modifications [23] . Briefly, 2 X 106 hMSCs stimulated with or without BMP2 for 72 h were 
collected by trypsinization and chromatin complexes were crosslinked by the addition of 1% 
formaldehyde for 15 minutes. Formaldehyde fixing was quenched by addition of cold glycine 
(final concentration - 125 mM), and the cells were collected by centrifugation. Cells were lysed 
(25 mM HEPES, 1.5 mM MgCl2, 10 mM KCl, 0.1% NP-40, 1 mM DTT, 0.5 mM PMSF, and 
protease inhibitors) on ice for 10 minutes to isolate nuclei. Nuclei were re-suspended in sonication 
buffer (50 mM HEPES, 140 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% sodium 
deoxycholate, 0.1% SDS, and protease inhibitors) and sonicated 20-cycles (30 second pulse, 30 
second rest on a Bioruptor pico, Diagenode) to isolate chromatin. Clarified chromatin was divided 
into two fractions after saving 10% as input samples, and 1 µg of Normal Rabbit IgG (Cell 
signaling Technology, 2729S) or RBPJ antibody (Cell signaling Technology, 5313S, 1:50 dilution) 
were added. The chromatin antibody complexes were incubated overnight at 4ºC on a rotating 
platform. Next day, protein G dynabeads (pre-blocked with 5% BSA, 30 µl per 
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immunoprecipitation condition) were added to capture the immune complexes for 1 h at 4ºC. The 
magnetic beads were extensively washed in a series of low- and high-salt wash buffers, LiCl wash 
buffer and Tris-EDTA buffer. The immune complexes were eluted, decrosslinked (overnight at 
65ºC), and treated with RNase for 30 minutes. Finally, DNA was purified from the eluate by using 
a Qiagen PCR cleanup kit (Cat. No. 28106). Each immunoprecipitated DNA sample was analyzed 
by real-time qPCR using specific primers (sequences are provided in the supplementary 
information and spanned regions containing putative RBPJ consensus sequence except for RUNX2 
promoter, where it couldn’t be identified). ChIP assays were repeated in three unique hMSC donor 
lines and relative enrichment for each condition was calculated using standard procedure.  
Calvarial defect model: 
All animals in this study were used in compliance with the University of Michigan guidelines and 
approved IACUC protocol. A group of C57Bl6 mice (n=18, age 14-20 weeks) underwent calvarial 
defect surgery as briefly described below. At the time of surgery, animals were anesthetized and a 
3 mm defect was drilled into each parietal bone using a piezo drill. A collagen sponge graft 
(Advanced Biomatrix SpongeCol 5135) was loaded with a solution containing 0.25 μg BMP2 and 
placed over the bone defect, and the incision was closed. Post-surgical, animals were closely 
monitored and received Buprenorphine injections every 12 hours for the next 48 hours. After 5 
days of surgery, animals were randomly assigned into groups and treated daily for the next 5 days 
with either 10 μg/kg Diabenzazepine (DBZ) or a vehicle control via intraperitoneal injection as 
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described previously for in vivo Notch inhibition [24]. After 42 days, whole calvariae were 
removed and fixed in 4% paraformaldehyde for 48 hours. Fixed calvariae were briefly rinsed with 
distilled water and transferred to 70% ethanol until scanned. Scanned microCT images were 
analyzed using Parallax Microview software and the extent of new bone formation determined as 
described previously [14]. 
Statistical analysis: 
Numerical values for each assay are reported as mean ± standard deviation. The number of donors 
assessed and replicates used for each experimental condition are mentioned in figure legends. A 
2-way homoscedastic Student’s t-test was performed to determine significant differences among 
experimental conditions. * represents significant difference (P ≤0.05) compared to control, and # 
represents significant difference between experimental groups (P ≤0.05). 
 
RESULTS 
Runx2 abrogation inhibits both Jagged1 and BMP mediated human osteoblast 
differentiation: 
We have previously demonstrated that Jagged1 induces hMSC osteoblast differentiation through 
canonical Notch signaling and requires concomitant PKCdelta signaling  [10] [13]. However, the 
role of osteoblast specific transcription factor Runx2 during Jagged1 induced hMSC osteoblast 
differentiation is unknown. We introduced siRNA against Runx2 in hMSC and stimulated targeted 
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cells with Jagged1 or BMP2 for 3 days after which ALP staining was carried out. Parallel plates 
received fresh osteogenic media until assessed for mineralization within 8-10 days. The 3 day 
time-point was chosen for histochemical ALP detection because earlier studies from our laboratory 
have demonstrated that the maximal ALP expression in BMP or Jagged1 stimulated hMSCs 
occurred between 72-96 hours after stimulation [10 25-27]. As shown by histochemical staining 
in figures 1A-1D (and respective quantification in the histograms below the scanned images), 
Runx2 silencing efficiently reduced both Jagged1 and BMP2 mediated ALP expression and 
extracellular matrix mineralization. Corresponding to staining results, quantitative RT-PCR 
analysis also revealed significant reduction of ALPL gene expression levels in Runx2 silenced cells 
(Supplementary figure 1A and 1D). Despite the reduction in alkaline phosphatase expression and 
reduction of extracellular calcium deposition in Runx2 silenced cells, the expression levels of 
canonical targets HES1, HEY1 (canonical Notch target genes) and ID1 (canonical BMP target 
gene) were not affected (instead the levels of HES1 and ID1 were further enhanced) 
(supplementary figure 1B, 1C and 1E) suggesting Runx2 directly regulates the osteoblastogenic 
fate of hMSCs in both Jagged1 and BMP treated cells, but does not directly affect signaling.   
To examine how Runx2 and Osterix (a downstream transcription factor for osteoblast 
differentiation) proteins are modulated under Notch stimulation, we prepared total cell lysate from 
non-targeted cells or Runx2 targeted cells and performed immunoblotting. Runx2 and Osterix were 
expressed in untreated cells and the levels of Runx2 and Osterix protein in control siRNA 
transfected cells significantly increased upon BMP2 stimulation (Figure 1E-G), but their levels 
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stayed relatively constant during Jagged1 stimulation (Figures 1H-J). As expected, Runx2 protein 
levels were very low in Runx2 siRNA targeted cells, both in basal and under stimulated conditions. 
Additionally, although Runx2 siRNA reduced Osterix expression mediated by BMP2 stimulation 
to baseline levels, the basal Osterix expression levels remained unchanged with Runx2 siRNA in 
both BMP2 and Jagged1 treated cells (Figures 1E, 1G, 1H, 1J, lanes 1 and 3). To demonstrate 
Notch processing was unaltered by Jagged-1 stimulation of Runx2 silenced cells, the levels of 
active Notch1 protein (Notch1 val1744) and Notch2 NTM (the transmembrane fragment generated 
before gamma secretase cleavage) were also determined (Figure 1H). Taken together, this suggest 
that although Runx2 is not required for basal Osterix expression, canonical Notch and BMP signals 
interact with endogenous Runx2 protein to initiate human osteoblast differentiation.       
Jagged1 and BMP2 stimulations result in the differential expression of relatively few 
common genes (RNA-seq) 
Considering that both Notch signaling and BMP signaling can mediate terminal osteoblastogenesis 
and were blocked by Runx2, we conducted RNA-seq on three unique donor lines after 3 days of 
stimulation with Jagged1 and BMP2 to understand the transcriptomic profile of differentiating 
osteoblast.  We chose 3 days of stimulation with each ligand because the expression of ALPL is 
highly elevated at this time-point but the cells have not yet mineralized. As summarized in figure 
2A, BMP2 treatment resulted in differential expression of 2906 genes (fold change 1.5 at a false 
discovery rate of <10%) of which 1749 were upregulated and 1157 were down regulated (Figure 
2A and Supplementary Table 1). Compared to BMP2, relatively fewer genes showed differential 
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regulation- 342 genes were differentially expressed, and included 167 upregulated, and 175 down 
regulated (Figure 2A and Supplementary Table 2).  Rather surprisingly, the genes that were co-
expressed by both stimulations were relatively limited, and only 45 genes showed common 
upregulation and 69 showed common downregulation (Figure 2B, supplementary figure 3, 6 and 
supplementary table 3). ALPL was among the top 10 commonly upregulated genes and also 
included a set of early osteoblast-associated genes including ACAN, HAS3, MCAM and OLFML2B 
(Figures 2C and 2D). It was particularly intriguing that three Notch signaling genes (JAG1, HEY2 
and HES4) were among the top 10 commonly upregulated genes (Figure 2C and 2D) and also 
included NOTCH3 within the top 45 suggesting Notch activation by both BMP2 and Jagged1 
during human osteoblast differentiation (supplementary tables 1, 2 and 3). Finally, two of the top 
10 commonly upregulated genes were a transcriptional regulator ID4 and NPTXR, a gene known 
to be involved in synaptic modulation (Figure 2C and 2D). Strikingly, Ingenuity Pathway Analysis 
of the top 45 commonly upregulated genes showed a similar trend obtained with the top 10 
commonly upregulated genes. The top 3 highly upregulated pathways were Notch signaling, 
Regulation of the Epithelial-Mesenchymal Transition Pathway, and Osteoarthritis pathway (Figure 
2C, Supplementary Figures 2 and 3). Furthermore, consistent with immunoblot results for Runx2 
and Osterix (Figure 1H), it was notable that while BMP2 upregulated RUNX2, SP7 (Osterix), 
SPP1, SOST, DKK1 and DMP1 (classical genes implicated in differentiated osteoblasts), 
expression levels of these genes did not significantly change in Jagged1 stimulated cells 
(supplementary tables 1and 2 and data not shown). 
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Next, we also considered the possibility of osteoblastic differentiation regulation by commonly 
downregulated genes. Among the top 10 commonly downregulated genes, we observed that 3 of 
the genes were SH3 domain containing proteins (SH3D19, UBASH3B, and SH3BP5) 
(supplementary table 3), which are known to affect protein phosphorylation. Intriguingly, SH3D19 
is also known to be involved in regulating ADAMs (A disintegrin and metalloprotease) [28] which 
affects the Notch signaling pathway. Considering upregulation of Notch signaling components in 
response to both BMP2 and Jagged1, we chose to further study the role of Notch in BMP mediated 
hMSC osteoblastogenesis. 
Notch signaling is required for BMP-mediated osteoblastogenesis 
Considering the upregulation of Notch signaling related genes by BMP revealed by RNA-seq, we 
determined if Notch signaling was required for BMP2-mediated human osteoblast differentiation. 
Cells were treated with DAPT (a gamma secretase inhibitor that blocks the generation of Notch 
intracellular domains) simultaneously with BMP (BMP2 and BMP6) at various time points after 
BMP stimulation. At the end of 96 h, alkaline phosphatase expression was histochemically 
determined. As shown in figure 3A, alkaline phosphatase expression in response to BMP was 
inhibited even when DAPT was added as late as 24 hours after BMP stimulation (Figure 3A). 
However, this inhibitory effect was gradually lost from 24 to 48 hours and no apparent reduction 
on alkaline phosphatase expression could be observed when DAPT was added 72h after BMP 
stimulation (Figure 3A). In a parallel set of experiment, extracellular matrix mineralization was 
determined by Alizarin red staining after 10 days (Figure 3B). As observed above for alkaline 
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phosphatase expression, simultaneous DAPT treatment completely blocked BMP-mediated 
extracellular calcium deposition (Figure 3B) and such inhibitory effect was maintained even when 
DAPT was added 24 h after the initial BMP treatment (Figure 3B). Notably, gamma-secretase 
inhibition became ineffective after 48 h of BMP stimulation and both alkaline phosphatase and 
extracellular calcium deposition are unchanged in cells treated with DAPT after 48 h of BMP 
stimulation.  In corresponding experiments, we determined how gamma secretase inhibition 
affected the expression of canonical BMP target gene ID1 (as well as ALPL) and examined how it 
affected the Notch target genes identified from our RNA-seq data, HEY2 and HES4. As shown in 
figures 3C, 3D, 3E and 3F, despite minimal effects on the BMP-mediated expression levels of ID1 
(Figure 3C) by DAPT, the expressions of ALPL, HEY2 and HES4 were significantly reduced by 
blocking Notch signaling with DAPT in the presence of BMP2. Further quantitative gene 
expression analysis on the top 10 commonly upregulated genes by BMP2 and Jagged1 also showed 
reductions in BMP2 and DAPT co-stimulated cells (data not shown).   
To investigate whether Notch proteins are activated by BMP stimulation and to assess the 
combined effect of gamma secretase inhibition on BMP signal transduction, we conducted 
immunoblotting experiments from cell lysate prepared after co-stimulation with BMP2 and DAPT. 
At first, we examined the effect of DAPT on BMP-mediated SMAD protein phosphorylation. As 
shown in figure 3G and 3H and supplementary figures 4A and 4B (first panel), there was no 
significant difference on the levels of SMAD phosphorylation elicited by BMP proteins in the 
presence of DAPT both in short-term (1 h) or longer treatment (72 h) durations. In further 
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experiments, the effect of DAPT on the expression of Runx2 and Osterix protein levels were 
examined. As shown by immunoblot experiment and quantitative analyses in Figures 3G, 3I and 
3J, DAPT did not affect the expression levels of Runx2 and Osterix but instead showed a slight 
increase that did not reach statistical significance. Similar to the results observed with BMP2, the 
effect of DAPT on BMP6 mediated Runx2 and Osterix proteins were minimal (supplementary 
figure 4B). Next, we also determined if Notch proteins are activated by BMP signaling by 
immunoblotting for Notch1, Notch2 and Notch3 proteins. Cleaved Notch1 antibody detects 
endogenous levels of the Notch1 intracellular domain only when released by cleavage between 
Gly1753 and Val1754 and is indicative of Notch1 activation. The Notch2 antibody detects 
transmembrane region (but not the intracellular domain generated by gamma secretase cleavage) 
and therefore, will show decreased expression when activated. Notch3 antibody, however, will 
show increased expression after gamma secretase activation as it can recognize both the 
transmembrane region and intracellular domain. Levels of Notch2 protein showed some reduction 
in BMP-stimulated samples and cleaved Notch1 and Notch3 (both full length and transmembrane) 
protein levels were increased by BMP stimulation (Figure 3G, lanes 1 and 2). Correspondingly, 
including DAPT during BMP stimulation reversed the BMP2’s effect on Notch proteins (Figure 
3G and 3K) suggestive of gamma secretase mediated Notch activation. Similar results were also 
obtained with BMP6 and showed that although Runx2 and Osterix protein expression are 
minimally affected, processing of Notch proteins in the presence of BMP was inhibited by DAPT 
(supplementary figure 4B). Collectively, these results suggest that Notch receptor cleavage is an 
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essential regulatory step in BMP-mediated osteoblastogenesis prior to 48 h of continuous BMP 
exposure. 
BMP increases Notch signaling concomitant with increases in osterix and ALP 
Given that BMP mediated alkaline phosphatase expression depends on Notch activation, we were 
interested to determine whether these two events are concurrent during osteoblast differentiation. 
Therefore, we devised a BMP-washout experiment to understand the minimal treatment duration 
of BMP required for alkaline phosphatase expression (Figure 4A). First, cells were stimulated with 
BMP-2 and then 4 h, 8 h, 24h, 48 h or 72 h later, received two consecutive media exchange to 
wash out residual BMP. At the end of 96 h, cells were stained for alkaline phosphatase expression. 
As shown in figure 4B and quantification in the right histogram, the minimum duration of BMP 
stimulation required for significant ALP expression was 24 hours, and by 48 hours the alkaline 
phosphatase expression levels was indistinguishable between cells that continuously received 
BMP for 96 hours suggesting that a 48 h of BMP treatment is required for high alkaline 
phosphatase expression. In corresponding experiments, we treated cells with BMP2 for various 
lengths of time ranging from 8h-96h and determined gene expression levels of ALPL and ID1 (a 
canonical BMP target). Quite strikingly, ID1 expression peaked earlier during the course of 
treatment (8 h) and gradually returned to baseline levels over the next 96 hours (Figure 3C), but 
ALPL expression followed a completely different course and showed gradual increase only after 
48 hours of BMP stimulation (Figure 3D).  
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In the next set of experiments, we determined the kinetics of Notch protein activation in cells 
stimulated with BMP for a total of 96 h. As shown in figure 4E, although SMAD phosphorylation 
occurred much faster and already peaked after 1 h of BMP stimulation (Figure 3E, first panel and 
data not shown), Osterix protein expression started to increase only after 48 hours after BMP 
treatment. Strikingly, processing of Notch proteins was obvious 24 hours after BMP stimulation 
and was clearly evident after 48 hours when we could observe an increase of activated Notch1 and 
Notch 3 protein levels and corresponding decrease of Notch2 NTM protein levels. Additional RT-
qPCR experiments to determine expression levels of HEY2, and HES4 also showed comparable 
trend with Notch processing and became significant at 24 h, a similar timeline with Notch 
processing (supplementary figure 5A, 5B and 5C). 
Given that ALPL expression was abrogated by gamma secretase inhibition (Figures 3A and 3D) 
and that alkaline phosphatase expression levels (Figures 4A and 4D) paralleled Notch activation, 
we postulated that Notch signaling is a critical event during BMP mediated alkaline phosphatase 
expression and extracellular calcium deposition. To demonstrate that the expression of Notch 
ligands also occurred and corresponds to the Notch processing, total RNA samples prepared from 
BMP stimulated cells for 8h were subjected to quantitative gene expression analysis. As shown in 
supplementary figure 4C, expression of JAG1, the most upregulated ligand of the Notch signaling 
pathway by osteogenic cells during bone fracture repair [10], was significantly increased by both 
BMP2 and BMP6. The expression of another Notch ligand JAG2 could also be observed in BMP 
stimulated cells (supplementary figure 4D). Expression of Notch delta ligands (DLL1, and DLL4) 
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showed minimal changes in response to either BMP stimulation (supplementary figures 4E, 4F 
and 4G). Since both BMP2 and BMP6 increased JAG1 expression in hMSCs, BMP stimulation of 
hMSCs seems to converge on Jagged1 expression followed by Notch processing and commitment 
to osteoblast differentiation. 
Canonical Notch signals via RBPJ is required for BMP-mediated human osteoblast 
differentiation 
To determine whether canonical Notch transcriptional signaling is required for BMP mediated 
osteoblastogenesis, we delivered RBPJ siRNA and examined the effect on terminal osteoblast 
differentiation. As shown in figures 5A and 5B (quantification data in figures 5C and 5D), blocking 
RBPJ significantly attenuated BMP mediated increase in alkaline phosphatase expression and 
extracellular calcium deposition. In further experiments, we also examined whether RBPJ 
silencing affected canonical BMP-SMAD signaling. As shown in figure 5E (first and second 
panels), while RBPJ siRNA completely reduced its corresponding protein expression, BMP 
mediated increase in SMAD1/5/9 phosphorylation was minimally affected suggesting that RBPJ 
silencing is not associated with impaired BMP-SMAD signaling. Quite intriguingly though, BMP2 
stimulation did not increase Runx2 and Osterix protein levels in in RBPJ silenced cells. This effect 
of RBPJ knockout on BMP-mediated Runx2 and Osterix protein expression is in contrast to the 
result obtained with gamma secretase inhibition because BMP-mediated Runx2 and Osterix 
protein expression levels are not affected by DAPT and BMP co-stimulation (Figures 3G, 3I, 3J 
and supplementary figure 2B). Nevertheless, as shown by quantitative gene expression analysis, 
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the expression levels of ID1 and JAG1 were not affected in cells lacking RBPJ (Figure 5I and 5K) 
possibly because these genes are already activated by 8h after BMP stimulation (Figure 4D and 
supplementary 2C), but the expression levels of ALPL (Figure 5J) and HEY2 (Figure 5L) (both of 
which showed increased expression after Notch activation (Figures 4E and supplementary 5A)) 
were significantly reduced. Taken together, these results suggest that RBPJ acts as a downstream 
regulatory molecule during BMP-mediated human osteoblast differentiation.  
RBPJ is bound at the human ALPL and SP7(Osterix) promoters 
Since abolishing RBPJ affected the expression of ALP, RUNX2 and Osterix protein expression in 
response to BMP2 stimulation, we were interested to determine whether RBPJ binds to the 
corresponding gene promoters. Thus, chromatin immunoprecipitation (ChIP) was carried out using 
hMSC cells stimulated with or without BMP2 for 72h and relative enrichment in RBPJ binding 
within various gene promoters of interest were determined. At first, RBPJ enrichment at the 
promoter of two canonical Notch target genes HES1 and HEY1 were examined. As shown in Figure 
6A and 6B, HES1 and HEY1 promoter DNA region were significantly enriched with RBPJ 
antibody, both under basal and BMP2 stimulated conditions. In corresponding experiments, RBPJ 
binding at the ALPL, SP7 (Osterix), and RUNX2 gene promoters were evaluated. As shown in 
Figures 6C and 6D, RBPJ binding could be endogenously observed in ALPL, SP7 (Osterix) 
promoters, that did not significantly change with BMP2 stimulation. However, relative RBPJ 
binding in the RUNX2 promoter region could not be observed (Figure 6E). A different promoter 
region further upstream in the RUNX2 promoter region also showed no significant enrichment 
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above normal rabbit IgG (data not shown). Collectively, these data suggest that RBPJ binding is 
present in the ALPL and SP7(Osterix) promoters and thereby can directly regulate their expression 
in BMP2 stimulated cells.  
Inhibition of Notch signaling reduces bone formation during BMP2 mediated calvarial 
defect healing of mice.   
Finally, we were interested to determine whether Notch signaling is an important determinant of 
bone formation during BMP2 mediated bone defect healing in mice. Therefore, calvarial defect 
were created in a cohort of 18 mice and implanted with collagen sponges containing BMP2. At 
day 5 of the surgery, mice were randomly grouped and either received vehicle injection or 
diabenzazepine (DBZ, a gamma secretase inhibitor) injection for the next 5 days to block in vivo 
Notch activation [24]. This temporal injection regimen was chosen because Notch ligands and 
receptors are found to be increased upto day 10 after the surgery from our earlier report [29]. At 
day 42 of the initial surgery, calvariae was harvested and analyzed by microCT. As shown in 
Figure 7A, the amount of bone formation in DBZ injected mice were reduced. Quantification of 
the bone volume (Figure 7B) showed that new bone formed was significantly decreased by DBZ 
injection of BMP2 treated mice. Collectively, these data suggest that Notch signaling is also an 
important driver of BMP2-induced bone formation in vivo.  
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DISCUSSION 
While BMP is considered a master-regulator of osteoblast differentiation, how BMP intersects 
with other signaling factors to regulate human osteoblast differentiation is still an active area of 
investigation. Our own work has shown that canonical Notch signaling in hMSC can increase 
osteoblastogenesis, but the interplay between Notch signaling and BMP has remained largely 
unexplored. In this body of work, we demonstrate that Runx2 remains a key driver of osteoblast 
differentiation, regardless of the osteogenic stimulus. Runx2 knockdown blocked both Jagged1 
and BMP2 mediated osteoblastogenesis. Although, the role of Runx2 in BMP mediated 
osteoblastogeneis is well-understood [30], the requirement for Runx2 in Notch mediated 
osteoblastogenesis is  a novel finding. Since RBPJ was also required for proper differentiation of 
hMSCs in response to BMP stimulation, it is quite possible that Runx2 and RBPJ intersect. Indeed, 
the essential role of RBPJ in osteoblastogenesis has been demonstrated by Prx-CRE mediated 
deletion of RBPJ in mouse osteoprogenitor cells, which led to the non-union of long bone fractures  
[31], similar to mice with Prx mediated deletion of BMP2 [32]. Intriguingly, during murine 
fracture healing [29] or in marrow ablation models [14], the expression of canonical Notch ligands 
increases well before mineralization. As such, it is probable that for proper osteoblastogenesis and 
bone formation to proceed, activated Notch, Runx2 and RBPJ proteins are required. Corresponding 
to this notion, removal of each of these three components in differentiating hMSCs led to inhibition 
of alkaline phosphatase expression and extracellular calcium deposition (Figures 1A-1D, 3A-3B, 
5A-5B and data not shown). Furthermore, in BMP stimulated hMSCs these three factors are 
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gradually attained over 48 h because the expression of JAG1 (supplementary figure 2C) is followed 
by the processing of Notch proteins after BMP stimulation and occurs concurrent with the 
increased expression of ALPL (Figures 4D and 4E). Indeed, our DAPT chase experiment supports 
this observation since gamma secretase inhibition by DAPT abolished alkaline phosphatase 
expression up to 24 h after BMP stimulation, but failed to do so after 48 h when Notch processing 
is complete. Correspondingly, Jagged1 stimulated hMSCs  show significant ALPL gene expression 
within 24 hours after stimulation [10]. And on top of that, putative RBPJ consensus sequence 
(CCTGGGAA) can be found in the human ALPL promoter around 326-319 bp upstream of the 
transcription start site and our chromatin immunoprecipitation data showed that this region is 
indeed bound by RBPJ protein in hMSCs (Figure 6C).  
Contrary to the positive effect of Notch signaling on human osteoblastogenesis, Notch signaling 
in mice is activated by hypoxia and has been shown to inhibit mouse MSC osteogenesis by 
antagonizing pro-osteogenic transcription by Runx2 [33][34][35]. This discrepancy on the effect 
of Notch on human and mouse MSC osteoblastogenesis is poorly understood and likely reflects 
differences in human and rodent cell models, or may reflect the plasticity between the four 
mammalian Notch receptors and the five different ligands. Further, this role of the Notch pathway 
might be cell stage specific because stimulation of the primary bone-marrow derived mouse MSCs 
with BMP-2 does not significantly increase the expression of Jag1 and Notch target gene Hey2 
(data not shown). However, direct Jagged1 delivery using osteoconductive scaffold increases bone 
formation in rodent calvarial defect models and additionally as shown in this study (Figure 7) 
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blockage of Notch signals during BMP2 mediated calvarial defect regeneration reduces bone 
volume [14]. This discrepancy between in vitro studies with mouse cells and human cells supports 
the necessity for translating rodent studies to human model systems.  
Our recent interactome study of differentiating human osteoblasts utilizing massively parallel 
ATAC-seq and Capture-C also supports requirement of crosstalk of BMP/SMAD signaling with 
other signaling pathways for proper human osteoblast differentiation [20]. As reported in the study, 
attenuating the expressions of ING3 and EPDR1, critical pro-osteoblastic genes, had no effect on 
canonical BMP/SMAD signals and expression of Runx2 protein, yet terminal osteoblast 
differentiation was abolished. Considering the results presented herein, it is quite reasonable that 
BMP-Notch cross-talk is an important driver of human osteoblast differentiation because 
abolishing Notch activation up to 24 hours after BMP stimulation had a negative effect on terminal 
osteoblast differentiation. Thus, it would be interesting to determine if components of the Notch 
pathways are adversely affected by the lack of these novel pro-osteoblastic genes.  
With regards to Jagged1 stimulation, although terminal osteoblast differentiation could be 
detected, increase in Runx2 and Osterix protein expression could not be observed. Since SMAD 
activation in response to BMP stimulation results in Runx2 and downstream Osterix expression 
[36], we assume that absence of SMAD/TAK1 activation with Jagged1 stimulation is the likely 
explanation for why Jagged1 stimulation does not impact Runx2 and Osterix expression. However, 
even though BMP-mediated SMAD activation was maintained, upregulation of both Runx2 and 
Osterix proteins were absent in RBPJ silenced cells (Figures 5E, 5G and 5H). Thus, it appears that 
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basal RBPJ expression may serve a non-canonical role in modulating RUNX2 and Osterix protein 
expression (and/or function). In partial agreement, RBPJ binding could be clearly observed at the 
Osterix promoter of hMSCs (Figure 6D), however we failed to detect such at the RUNX2 promoter 
(Figure 6E). Further, relatively few (Figure 2B) commonly upregulated (total 45 genes) and down 
regulated genes (total 69 genes) were observed by RNA-seq during Jagged1-mediated 
osteoblastogenesis and BMP2-mediated osteoblastogenesis. However, of these genes commonly 
upregulated, Ingenuity Pathway Analysis revealed that they represent genes of Connective Tissue 
Development and Function, Organ Morphology, Organismal Development, and Skeletal and 
Muscular System Development and Function, as four of five top Physiological System 
Development and Function Pathways. As mentioned earlier, the transcriptome analysis was 
performed with cells that haven’t begun to mineralize, thus the list of co-regulated genes may only 
represent key early mediators in osteoblast differentiation. Therefore, it would be interesting to 
perform a longitudinal experiment that focusses on teasing out differentially expressed genes at 
various stages of differentiation. Also, except for the JAG1 and ALPL, none of the top 10 
commonly upregulated gene show enriched Runx2 binding in ChIP-seq performed with 
immortalized hMSCs [37].  The essential role of these genes in the process of osteoblastogenesis 
will need to be elucidated, although one, ALPL is a well-recognized key mediator of osteoblast 
mineralization, for which we provide Notch pathway involvement using pharmacological as well 
as genetic evidence. Despite such, the alterations in ACAN, HAS3, MCAM, and OLFMl2B (as well 
as ALPL) also should carry profound effects on mineralization.  
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In the pathway analysis, whether using the top 10 commonly upregulated genes or all of the 45 
upregulated genes, Notch signaling stood as the top Canonical Pathway identified as common 
between BMP and Notch induced osteoblastogenesis, suggesting a key role for Notch signaling in 
BMP-induced osteoblastogenesis. Indeed, we show that BMP induces Notch signaling, both at the 
gene expression and protein level, including upregulating both ligand and receptor expression, and 
that inhibiting Notch signaling - either at the level of receptor cleavage using DAPT or genetically 
by disrupting RBPJ - blocks terminal osteoblast differentiation, although it cannot be ruled out that 
RBPJ has non-canonical effects, as its absence does also result in a decrease in Runx2 and Osterix 
protein expression after BMP stimulation of hMSCs. 
This work has important implications for understanding the process of osteoblastogenesis, and the 
interplay between Notch and BMP signaling.  While BMP is a potent osteoblastogenic agent, the 
role for Notch signaling in osteoblastogenesis is more controversial. Humans with loss-of-function 
mutations in JAG1 have decreases in bone mass and osteopenia, and it could be that the decrease 
in Jagged1 ligand during the process of osteoblastogenesis contributes to reduced bone formation.  
Indeed, mouse studies with disruption of Jag1 in osteoprogenitor cells suggest decreases in bone 
volume [38]. Future studies will attempt to uncouple Notch and BMP signaling pathways in 
osteoblastogenesis, and to explore these intersections in animal models.  
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LEGENDS FOR FIGURES 
Figure 1:  
Runx2 knockdown impairs human osteoblast differentiation in response to both Jagged1 
and BMP2. (A-B) Runx2 siRNA transfected hMSC were stimulated with or without Jagged1 
(A) or BMP2 (B) for 3 days and alkaline phosphatase expression was histochemically 
determined. Bottom histogram depict mean value of staining results using quantitative imaging 
from three independent donor lines. (C-D) Extracellular calcium deposition was histochemically 
determined by Alizarin red S staining of Runx2 siRNA transfected cells stimulated with or 
without Jagged1 (C) or BMP2 (D) for 10-12 days.  Bottom histogram depict mean value of 
staining results using quantitative imaging from three independent donor lines. (E) Protein 
expression of Runx2, Osterix and RBPJ were determined in Runx2 siRNA transfected cells 
stimulated with or without BMP2 for 3 days. The levels of GAPDH was used as a loading 
control. Relative band densities for Runx2 (F) and Osterix (G) were determined using four 
different donor lines. (H) Protein levels of Runx2, Osterix, and RBPJ were determined in Runx2 
siRNA transfected cells stimulated with or without Jagged1 for 3 days. The levels of GAPDH 
was used as loading control. Relative band densities for Runx2 (F) and Osterix (G) were 
determined using four independent experiments from two independent donor lines. 
Columns = mean. Error bars = Standard deviation. *p<0.05 comparing No treatment to respective 
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treatment with Jagged1 or BMP2 for each siRNA, #p < 0.05 comparing control siRNA to siRNA 
for gene of interest (two-way homoscedastic Student’s t-tests).  
 
Figure 2:  
Notch signaling components are upregulated by both BMP and Jagged1 stimulation of 
human mesenchymal stem cells. (A) Total RNA samples prepared from three unique hMSC 
donor lines stimulated with BMP2 or Jagged1 for 3 days in osteogenic media were subjected to 
RNA sequencing on the Illumina NovaSeq platform. Total number of differentially expressed 
genes at a false discovery rate of <10% for each treatment group relative to its control group is 
shown (upregulated (upward facing green arrow), downregulated (downward facing arrow), and 
total (central oval)). (B) Venn diagrams of total number of commonly overlapping BMP2 and 
Jagged1 upregulated genes (45) shown in blue and downregulated genes (69) shown in red were 
determined by intersecting the data for upregulated genes and downregulated genes (FC>1.5) 
under each treatment condition. (C) Ingenuity Pathway Analysis of the top 10 genes out of the 
45 commonly upregulated genes are depicted, and (D) Categorization of the top 10 commonly 
upregulated gene by biological processes. 
 
Figure 3: 
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Gamma-secretase inhibitor impairs BMP-mediated human osteoblast differentiation. (A) 
Cells were stimulated with BMP2 or BMP6 (300 ng/ml) and immediately treated with DAPT or 
DAPT treated after 8h, 24h, 48h and 72h of the initial BMP stimulation. At the end of 96h after 
initial BMP exposure, alkaline phosphatase expression was histochemically determined. (B) 
Extracellular calcium deposition was histochemically determined after 10 days by Alizarin red S 
staining of cells stimulated as above. (C-F) Quantitative gene expression of ID1, ALPL, HEY2 
and HES4 in hMSCs stimulated for 72h with BMP2 with or without DAPT. (G) Protein 
expression of P-SMAD1/5/9, Runx2, Osterix, Notch1 (val 1744), Notch2 (NTM), Notch3 (FL), 
and Notch3 (NTM) were determined in cells stimulated with BMP2 in presence or absence of 
DAPT for 72h. The levels of GAPDH was used as a loading control. Relative band densities for 
P-SMAD1/5/9 (H), Runx2 (I), Osterix (J) and Notch3 (NTM) were calculated using three 
different donor lines. Gray columns = No DAPT; Black columns = DAPT treatment. 
Columns = mean. Error bars = Standard deviation. *p<0.05 comparing No treatment to BMP2 
treatment, #p < 0.05 comparing control siRNA to siRNA for gene of interest, n.s = not significant 
(two-way homoscedastic Student’s t-tests). 
 
Figure 4:   
Notch activation and Osterix protein expression co-occur with alkaline phosphatase 
expression in BMP2 stimulated human mesenchymal stem cells. (A) Experimental outline to 
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determine the effect of BMP washout in alkaline phosphatase expression. (B) Cells were 
stimulated with BMP2 and at the indicated times received two washes with osteogenic media 
from indicated wells. After a total of 96h after initial BMP stimulation, alkaline phosphatase 
expression was determined by histochemical staining. Right histogram depicts relative alkaline 
phosphatase expression determined by quantitative image analysis of the stained wells depicted 
in (B). For the well stimulated with BMP2 without any washout for 96h, the levels of alkaline 
phosphatase expression level were arbitrarily set at 100%. (C-D) Quantitative gene expression of 
(C) ID1 and (D) ALPL was determined in cells stimulated with BMP for up to 96h as indicated. 
(E) Protein expression of P-SMAD1/5/9, Osterix, Notch1 (VAL 1744), Notch2 (NTM) and 
Notch3 (NTM) were determined in BMP stimulated cells for indicated times. GAPDH was used 
as internal control.  *p<0.05 comparing No treatment to BMP2 treatment, #p < 0.05 comparing 
No washout to washout at indicated times, n.s = not significant (two-way homoscedastic 
Student’s t-tests).  
 
Figure 5:  
Canonical Notch signaling via RBPJ is required for BMP mediated human osteoblast 
differentiation. (A) RBPJ siRNA transfected hMSC were stimulated with or without BMP2 for 
3 days and alkaline phosphatase expression was histochemically determined. (B) Extracellular 
calcium deposition was histochemically determined by alizarin red S staining of RBPJ siRNA 
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transfected cells stimulated with or without BMP2 for 10 days. (C) Quantitative image analysis 
from three independent hMSC donor lines to determine relative alkaline phosphatase expression 
in RBPJ siRNA transfected cells. (D) Quantitative image analysis from four independent hMSC 
donor lines were combined to determine relative mineralization levels. (E) Protein levels of 
RBPJ, P-SMAD1/5/9, Runx2 and Osterix were determined in RBPJ siRNA transfected cells 
stimulated with or without BMP2 for 72 hours. The levels of GAPDH were used as internal 
control. (F-H) Densitometric analysis of immunoblot experiments as in (E) from three 
independent donor lines were performed to enumerate relative band densities for RBPJ (F), 
Runx2 (G), and Osterix (H). (I-L) Quantitative gene expression analysis to determine relative 
expression levels of ID1 (I), ALPL (J), JAG1 (K), and HEY2 (L) in four independent hMSC 
donor lines after RBPJ silencing. Gray columns = No BMP; Black columns = BMP treatment. 
Columns = mean. Error bars = Standard deviation. *p<0.05 comparing No treatment to BMP2 
treatment, #p < 0.05 comparing control siRNA to RBPJ siRNA (two-way homoscedastic 
Student’s t-tests).  
 
Figure 6:  
RBPJ is bound at the human ALPL and SP7 promoter regions. (A) Upper panel: Schematic 
depiction of chromatin immunoprecipitation (ChIP) primer locations (arrowheads) in the human 
HES1 promoter region. Location +1 and a turning arrow above it represents the transcription start 
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site. Lower histogram:  hMSC were stimulated with or without BMP2 for 3 days in serum-free 
osteogenic media and chromatin immunoprecipitation (ChIP) was performed with either normal 
rabbit IgG or anti-RBPJ antibody. Relative enrichment of DNA compared to input samples were 
calculated for each immunoprecipitation reaction and presented. (B-E) Schematic representation 
of ChIP primer locations and relative enrichment of DNA compared to input samples around (B) 
HEY1, (C) ALPL, (D) SP7 and  (E) RUNX2 gene. ChIP experiments were performed in 3 
independent hMSC donor lines. Gray columns = No BMP; Black columns = BMP treatment. 
Columns = mean. Error bars = Standard deviation. *p<0.05 comparing normal rabbit IgG to 
RBPJ antibody (two-way homoscedastic Student’s t-tests).  
 
Figure 7:  
Pharmacological Notch inhibition using dibenzazepine (DBZ) reduces bone volume during 
BMP2 mediated calvarial defect healing of mice. (A) Representative microCT images taken at 
day 42 of calvarial defects of a vehicle and DBZ treated mouse. All 18 animals received 0.25µg 
BMP2 on the day of calvarial defect surgery and received intraperitoneal injections of either 
vehicle (n=9) or DBZ (n=9) on days 5-9 after the surgery. (B) Bone volume (BV) was measured 
across animals that received vehicle or DBZ injections as described above. *p<0.05 comparing 
vehicle control to DBZ treated group (two-way homoscedastic Student’s t-tests) 
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